[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Joseph Tung, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and the award was recorded at $0. The RSUs vest in three equal installments, with one-third vesting on each of 08/08/2026, 08/08/2027 and 08/08/2028, and the reported ownership form is direct. Following this reported transaction, the RSUs correspond to 29,240 underlying shares.

The filing discloses an equity award that aligns a director with shareholder interests via long-term vesting, but it does not provide the company’s total outstanding share count or other compensation terms needed to assess dilution or material financial impact.

Positive

• Alignment with shareholders: The director grant vests over multiple years, linking compensation to long-term performance
• Size of award disclosed: 29,240 RSUs explicitly reported and documented

Negative

• No outstanding share count provided: The filing does not include company share totals, so potential dilution cannot be assessed from this form
• No additional compensation terms disclosed: Other economic terms or reasons for the grant are not included in this Form 4

Insights

Corporate Governance Expert

TL;DR: Director equity grant of 29,240 RSUs with multi-year vesting signals alignment but is likely routine and not clearly material.

The grant to Joseph Tung vests one-third annually over three years, which is a standard retention and alignment structure for board members. The award is directly held and converts one-for-one to common shares, recorded at $0, which indicates a typical restricted award rather than a purchase. The filing lacks context on outstanding shares or board compensation policy, so the governance implication is positive for alignment but the materiality to shareholders cannot be quantified from this form alone.

Securities Analyst

TL;DR: A 29,240-RSU grant is disclosed; without share-count context this is informational and unlikely to be material to valuation.

This Form 4 shows an acquisition (grant) of 29,240 RSUs exercisable into 29,240 common shares and vesting across 2026–2028. The reported price is $0, consistent with standard RSU awards rather than an option exercise or purchase. Because the filing does not disclose the company’s outstanding shares or other recent insider activity, the transaction should be treated as routine insider compensation rather than a market-moving event based solely on the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tung Joseph

(Last) (First) (Middle)

C/O SHUTTLE PHARMACEUTICALS HOLDINGS

401 PROFESSIONAL DRIVE, SUITE 260

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/08/2025		A		29,240		(2)	(2)	Common Stock	29,240	$0	29,240	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU"s) represents the contingent right to receive one share of common stock.

2. One-third of these RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028.

	/s/ Joseph Tung	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Joseph Tung report in the SHPH Form 4?

The Form 4 shows Joseph Tung was granted 29,240 RSUs on 08/08/2025, each representing one share of common stock and recorded at $0.

How do the 29,240 RSUs vest for SHPH director Joseph Tung?

The RSUs vest in three equal installments: one-third on 08/08/2026, one-third on 08/08/2027, and one-third on 08/08/2028.

Is the reported ownership direct or indirect for the SHPH grant?

The filing reports the ownership form as Direct (D) for the 29,240 RSUs.

Was any cash paid for the RSUs in the SHPH Form 4?

No cash consideration is reported; the RSUs are recorded at a price of $0.

Does the Form 4 state how many shares the RSUs represent after vesting?

Yes. Each RSU represents one share, so the award corresponds to 29,240 underlying common shares upon settlement.